Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amneal Pharmaceuticals ( (AMRX) ) just unveiled an update.
Amneal Pharmaceuticals announced a reduction in its Board of Directors from six to five members due to a decrease in the ownership of Class A Common Stock by the Amneal Group. This led to the resignation of Emily Peterson Alva from the Board on July 16, 2025. The company also reported preliminary financial results for the second quarter of 2025, showing a net revenue increase of approximately 3% and a significant rise in income before taxes compared to the same period in 2024. The results highlight Amneal’s continued financial strength and deleveraging efforts, with expectations to meet or exceed full-year guidance. The quarter also saw the FDA approval of Brekiya® autoinjector and strong commercial uptake of CREXONT®, positioning Amneal well for future growth.
The most recent analyst rating on (AMRX) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Amneal Pharmaceuticals stock, see the AMRX Stock Forecast page.
Spark’s Take on AMRX Stock
According to Spark, TipRanks’ AI Analyst, AMRX is a Neutral.
Amneal Pharmaceuticals’ overall score is driven by solid revenue growth and a positive earnings call outlook, despite high leverage and profitability challenges. The lack of valuation appeal and neutral technical indicators moderate the score.
To see Spark’s full report on AMRX stock, click here.
More about Amneal Pharmaceuticals
Amneal Pharmaceuticals is a diversified pharmaceutical company that focuses on the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The company is known for its robust pipeline and commitment to delivering long-term growth through innovation and strategic market positioning.
Average Trading Volume: 1,765,281
Technical Sentiment Signal: Buy
Current Market Cap: $2.5B
See more insights into AMRX stock on TipRanks’ Stock Analysis page.